Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia

Clinical Trial Details

This trial is open to women and men age 55 and older with active, relapsed or refractory acute myeloid leukemia (AML). Iomab-B is a drug that allows targeted delivery of the radiation dose directly to leukemic cells while limiting radiation exposure to normal organs that are not sites of disease. This treatment will be a way of reducing the disease without excessive toxicity prior to a hematopoietic stem cell transplant (HCT). 

The primary objective of this study is to demonstrate the effectiveness of Iomab-B, in combination with a protocol-specific allogeneic HCT regimen, versus conventional care. 

Subject will undergo screening prior to randomization into one of the following groups: 

  • Iomab-B Treatment Group 
  • Conventional Care Treatment Group- subject will be assigned to the investigator’s choice of chemotherapy regimen 
  • Subjects will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.
Key Eligibility: 
  • Women and men age 55 and older 
  • Have active, relapsed or refractory AML 
  • Detailed eligibility reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan


Ashlee N. Torres, RN
(212) 746-7117

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group